| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Oncolytic Viruses | Oncology |
Recent Updates
Recently added Catalysts
Calidi Biotherapeutics, Inc.$0.1
0 (-4.76%)
Market Cap
3.39 M
EPS
-5.18
P/E Ratio
-
Value Trade
2.34 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.59 M
Operating CF
-4.12 M
Total Assets
9.59 M
Total Liabilities
4.66 M
Equity
4.93 M
D/E Ratio
12,345
9.88 %
Week
-26.75 %
1 Month
-78.48 %
3 Month
-86.98 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
6.63 M
Monthly Burn
1.37 M
Runway
2.6 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
40.14 M
52 Week Range
0.16 - 19.20
% held by Insiders
10.11 %
% held by Institutions
10.45 %
Enterprise Value
-1.08 M
Total Shares
15.22 M
Short %
23.54 %
Float Shares
14.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Calidi Biotherapeutics, Inc.
198Total events
14Upcoming
19Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 2
TBD
T2Reverse Stock Split
Subscribe to view catalyst details
TBD
T2Oral Presentation
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Poster PresentationCLD-501Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RTNova | metastatic lung cancer | — | 2024-11-18 | robust therapeutic potential | Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer Read More | |
RTNova | metastatic lung cancer | — | 2024-11-18 | robust therapeutic potential | Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer Read More | |
RTNova | metastatic lung cancer | — | 2024-11-18 | robust therapeutic potential | Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLDI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLDI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLDI▼ -13.9%on this news
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Calidi Biotherapeutics provided a mid-year update highlighting positive pre-IND feedback from the FDA for its lead candidate CLD-401, which is set to enter a first-in-human study in Q1 2027. The company showcased advancements in its RedTail platform, including new data on in situ T-cell engagers. Additionally, Calidi has reduced its general and administrative costs significantly and strengthened its Board with experienced executives.
Read more →CLDI▼ -13.9%on this newsshared move
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics announced a 1-for-16 reverse stock split, effective July 31, 2026. This decision aims to enhance market dynamics and attract more investors. Stockholders will see their shares consolidated, with adjustments made for fractional shares. The company continues to develop its RedTail platform for targeted genetic therapies.
Read more →CLDICalidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics presented new data on its T-cell engager candidate CLD-501 at the T-cell Engager Therapeutic Summit. The data highlights the efficacy of the RedTail platform in activating T-cells and expressing T-cell engagers directly in the tumor microenvironment. This approach aims to address challenges faced by T-cell engagers in solid tumors, particularly with TROP2 targeting.
Read more →CLDICalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics has appointed Dr. Corsee Sanders to its Board of Directors, effective June 17, 2026. Dr. Sanders brings a wealth of experience from her previous roles at Genentech/Roche and Celgene. Her expertise in the clinical development of novel therapeutics is anticipated to significantly benefit Calidi as it advances its lead candidate, CLD-401, and the RedTail platform.
Read more →CLDICalidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Calidi Biotherapeutics has received favorable pre-IND feedback from the FDA regarding its development strategy for CLD-401, a targeted oncolytic virus therapy. This feedback aligns with the company's plans to initiate a first-in-human clinical trial in early 2027. The FDA's agreement on key aspects of the clinical study design supports Calidi's IND-enabling efforts.
Read more →CLDICalidi Biotherapeutics Announces Investor Webinar on June 9, 2026
Calidi Biotherapeutics will host an investor webinar on June 9, 2026, featuring CEO Eric Poma. The event will cover the RedTail platform's advancements, including the lead candidate CLD-401, which targets various cancers. The discussion will also highlight upcoming milestones and the platform's broader potential. A live Q&A will follow the presentation.
Read more →CLDICalidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
Calidi Biotherapeutics announced the acceptance of two abstracts for the 2026 ASCO Annual Meeting, showcasing their RedTail platform's capabilities. The company will present preclinical data on its lead programs, CLD-401 and CLD-501, which aim to enhance immune responses against tumors. Calidi plans to file an IND for CLD-401 by the end of 2026, while continuing to seek strategic partnerships.
Read more →CLDI▼ -8.4%on this newsshared move
Calidi Biotherapeutics Provides Required NYSE American Disclosure
Calidi Biotherapeutics disclosed that its Financial Statements for 2025 included an audit report highlighting the assumption of continuing as a going concern. This disclosure is mandated by NYSE regulations and does not alter previous filings. The company is advancing its RedTail platform, targeting various cancers with its lead candidate, CLD-401.
Read more →CLDI▼ -5%on this news
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its Q1 2026 financial results, highlighting advancements in its CLD-401 and RedTail platform. The company presented new data at the AACR conference, showcasing immune changes induced by CLD-401 and the innovative use of T-cell engagers. A strategic partnership with TransferAI aims to enhance the IND submission process, while the company recorded a significant reduction in administrative expenses.
Read more →CLDI▲ +8.1%on this newsshared move
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
Calidi Biotherapeutics will feature Dr. Antonio F. Santidrian at the ASGCT Conference in Boston, discussing the promising RedTail platform and its lead candidate CLD-401. This virotherapy aims to selectively target tumors and enhance immune response. The company plans to file an IND for CLD-401 by the end of 2026.
Read more →CLDI▼ -6.9%on this news
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
Calidi Biotherapeutics has announced a strategic partnership with TransferAI to enhance the IND submission process for its lead candidate, CLD-401, utilizing TransferAI's artificial intelligence platform, Sofie. This collaboration aims to streamline regulatory workflows and support Calidi's objective of submitting its IND by the end of the year. CLD-401, part of the RedTail platform, is designed to target tumors effectively by utilizing an engineered oncolytic virus. The partnership is expected to bolster Calidi's regulatory efforts as it advances towards clinical trials for this promising therapeutic candidate.
Read more →CLDI▼ -11.4%on this news
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics presented new data on its lead asset, CLD-401, at the AACR Annual Meeting in San Diego on April 21, 2026. CLD-401 is an oncolytic virus designed to express high levels of IL-15 superagonist within the tumor microenvironment and has shown promising results in preclinical models. The company plans to file an IND application by the end of 2026, aiming to enter clinical trials soon after. This data highlights the potential of Calidi's RedTail platform to enhance immune response against various cancers.
Read more →CLDI▼ -9%on this news· ran to -20% by day 3shared move
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics presented new data at the AACR annual meeting highlighting its RedTail platform's ability to activate T-cells while delivering T-cell engagers directly in the tumor microenvironment. The company is also developing CLD-501, a candidate specifically targeting TROP-2, a challenge due to potential off-target toxicity. The platform aims to overcome historical limitations seen in solid tumors by remodeling the tumor environment for better T-cell efficacy. Calidi aims to expedite the clinical development of its therapies while pursuing additional targets.
Read more →CLDICalidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Calidi Biotherapeutics, a biotechnology company, will participate in the RedChip investor conference on April 16, 2026, highlighting its clinical advancements. The company is developing the RedTail platform, focusing on delivering targeted genetic medicines to tumors. Calidi aims to file an IND for its key candidate CLD-401 by the end of the year. Challenges include the need for funding and uncertainty regarding FDA approvals.
Read more →CLDICalidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
Calidi Biotherapeutics will present new data on its RedTail system at the ASGCT annual meeting in Boston on May 14, 2026. The RedTail platform is designed to deliver genetic medicines targeting tumors while limiting peripheral exposure. Highlighted data show the platform's ability to evade immune clearance and deliver concentrated genetic therapies directly to disease sites. The company expects to file an IND for its lead candidate, CLD-401, by the end of 2026, further advancing its cancer treatment pipeline.
Read more →CLDICalidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics will present new data on its lead asset CLD-401 at the AACR Annual Meeting in April 2026. The data will focus on the expression of IL-15 superagonist in the tumor microenvironment and its immune effects. The company aims to file an IND for CLD-401 by the end of 2026, highlighting its potential in treating various cancers.
Read more →CLDICalidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics will present new data at the AACR annual meeting in April 2026, focusing on its RedTail platform that activates T-cells and expresses T-cell engagers in situ within the tumor microenvironment. The lead candidate, CLD-401, aims to target solid tumors effectively by limiting off-tumor toxicity. The company plans to file an IND for CLD-401 by the end of 2026.
Read more →CLDI▼ -11.7%on this newsshared move
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its financial results for Q4 and full-year 2025, highlighting a net loss of $4.1 million for Q4 and $25.6 million for the year. The company is progressing with its lead candidate CLD-401 and has expanded its RedTail platform. Despite financial losses, Calidi remains optimistic about its future developments.
Read more →CLDICalidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
Calidi Biotherapeutics has partnered with Avance Clinical to facilitate the regulatory approval and clinical trial initiation for CLD-401 in Australia. This partnership aims to quickly start a first-in-human trial for CLD-401, a genetically modified virus targeting solid tumors. Calidi is also pursuing an IND filing with the FDA in 2026, indicating a proactive approach to clinical development.
Read more →CLDICalidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
Calidi Biotherapeutics presented its scalable manufacturing process for CLD-401 at the BioProcessing Summit. The proprietary RedTail platform targets tumor cells and enhances therapeutic gene expression. The FDA's feedback on the manufacturing strategy supports its clinical development. Calidi plans to submit an IND application for CLD-401 by the end of 2026.
Read more →CLDICalidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics announced the successful closing of its underwritten public offering, generating approximately $6.0 million in gross proceeds. The company sold over 12 million shares alongside various warrants, benefiting from strong investor interest as indicated by the full exercise of the underwriters' over-allotment option. The proceeds will support ongoing development of Calidi's targeted genetic medicine initiatives, particularly its lead candidate, CLD-401 for cancer treatment. The Series J, K, and L warrants are structured with favorable conditions for investors, suggesting a solid foundation for future growth.
Read more →CLDICalidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Calidi Biotherapeutics has announced a public offering of 10,519,631 units priced at $0.50 each, aiming to raise approximately $5.2 million. The offering includes warrants that could potentially raise an additional $10.4 million within a year. The proceeds will be used for working capital and corporate purposes. The offering is expected to close on March 9, 2026.
Read more →CLDICalidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics, a biotechnology firm based in San Diego, announced its intention to conduct an underwritten public offering of units that include common stock and pre-funded warrants. The company plans to utilize the net proceeds from this offering for working capital and general corporate purposes. Investors will have the option to purchase additional shares through an underwriters' option. The offering is subject to market conditions and may face uncertainty regarding its completion and terms.
Read more →CLDI▲ +8%on this news
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
Calidi Biotherapeutics presented promising data on its RedTail platform for BiTEs at the AACR-IO conference. The platform aims to enhance T-cell activation in solid tumors by delivering therapeutic payloads directly within the tumor microenvironment. The lead candidate, CLD-401, is currently in IND-enabling studies, with an IND application expected by the end of 2026.
Read more →CLDI▼ -6.9%on this news
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
Calidi Biotherapeutics will present its innovative RedTail platform at the AACR-IO conference, focusing on its application in bispecific T-cell engagers for solid tumors. The platform aims to remodel the tumor microenvironment and enhance T-cell activity. CLD-401, the lead candidate, is undergoing IND-enabling studies with an expected submission by late 2026.
Read more →CLDICalidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
Calidi Biotherapeutics provided a corporate update highlighting its achievements in 2025 and outlining key milestones for 2026. The company is advancing its RedTail platform, which targets tumor cells while minimizing systemic exposure. The lead candidate, CLD-401, is in IND-enabling studies, with an IND application expected by year-end. The CEO expressed pride in the team's accomplishments and the platform's potential.
Read more →CLDICalidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
Calidi Biotherapeutics will host a live investor webinar on November 19, 2025, featuring insights into its RedTail platform for delivering genetic medicines to tumors. The platform has shown promising preclinical results, demonstrating its ability to evade immune detection and effectively target metastatic sites. The company is also progressing towards an IND filing by the end of 2026.
Read more →CLDICalidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its third quarter 2025 financial results, highlighting advancements in its RedTail platform for delivering genetic therapies. The company is excited about its lead candidate, CLD-401, which is moving into clinical trials. Despite a net loss of $5.2 million, Calidi has built a strong scientific advisory board to support its efforts.
Read more →CLDICalidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
Calidi Biotherapeutics presented new data on its lead candidate CLD-401 at the SITC Annual Meeting, demonstrating its ability to target metastatic tumors effectively. The RedTail platform allows for systemic delivery of genetic medicines while minimizing systemic exposure. The company plans to submit an IND application by the end of 2026 and is pursuing strategic partnerships to enhance clinical development.
Read more →CLDICalidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
Calidi Biotherapeutics announced an investor event at the SITC Annual Meeting on November 7th, focusing on its RedTail platform and lead candidate CLD-401. The event will include a presentation and live stream, highlighting the company's progress in developing targeted genetic medicines. Calidi is currently conducting IND-enabling studies for CLD-401, which targets several cancer types.
Read more →CLDI▲ +6%on this newsshared move
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
Calidi Biotherapeutics announced new data on its therapeutic candidate CLD-401, set to be presented at the SITC Annual Meeting. CLD-401 is designed to target metastatic tumors and induce an immune response through the delivery of IL-15 superagonist. The company is in the process of conducting IND-enabling studies with plans to submit an IND application by the end of 2026. While the new data is promising, there are uncertainties related to funding and the predictability of early clinical trial results.
Read more →CLDI▼ -5.3%on this news
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
Calidi Biotherapeutics has established a Scientific Advisory Board to enhance the development of its RedTail platform and advance its lead candidate, CLD-401, into clinical trials. The board comprises prominent figures in drug development and oncology, who will guide the company in its mission to deliver targeted genetic medicines. CLD-401 aims to target metastatic cancer sites and induce immune responses in tumors.
Read more →CLDICalidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics announced its participation in the Oncology Venture, Innovation, and Partnering Summit in Boston. CEO Eric Poma will discuss the company's RedTail platform, which aims to deliver genetic medicines to cancerous sites. The platform is currently in IND-enabling studies targeting various cancers, including non-small cell lung cancer and ovarian cancer.
Read more →CLDICalidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Calidi Biotherapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025. CEO Eric Poma will highlight the company's RedTail platform, which aims to deliver genetic medicines to metastatic cancer sites. The company is focused on developing therapies for high unmet medical needs, particularly in non-small cell lung cancer and ovarian cancer.
Read more →CLDICalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics has successfully closed a $6.9 million underwritten public offering, including the full exercise of the underwriters' over-allotment option. The offering consisted of common stock units and pre-funded warrant units, aimed at advancing the company's innovative therapies targeting various cancers. This funding is expected to bolster Calidi's ongoing clinical studies.
Read more →CLDI▼ -42.7%on this newsshared move
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics has announced the pricing of an underwritten public offering, aiming to raise $6 million. The offering includes common stock units and pre-funded warrant units, with a closing expected on August 21, 2025. The transaction has garnered support from existing shareholders and new investors, reflecting confidence in the company's future.
Read more →CLDICalidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its second quarter 2025 financial results, showing a reduced net loss of $5.7 million compared to $7.4 million in 2024. The company highlighted progress in its RedTail platform, which aims to deliver genetic therapies to metastatic sites. Despite a decrease in cash reserves, Calidi remains optimistic about its therapeutic candidates targeting critical cancer types.
Read more →CLDI▲ +14.9%on this news
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
Calidi Biotherapeutics has received FDA Fast Track designation for CLD-201, a novel stem-cell loaded oncolytic virus aimed at treating soft tissue sarcoma. This designation is intended to expedite the development and review process for drugs addressing serious conditions. The company plans to initiate a Phase 1 trial to evaluate CLD-201's safety and efficacy in various advanced tumors.
Read more →CLDI▼ -5.4%on this news· ran to -29% by day 1shared move
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Calidi Biotherapeutics, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-12, effective on August 5, 2025. This decision, approved by stockholders at the recent annual meeting, aims to enhance market dynamics and broaden investor appeal. Following the split, every twelve shares will consolidate into one, allowing for automatic adjustments for most stockholders. Calidi continues to develop targeted therapies for various cancers using its proprietary Redtail platform, reflecting its commitment to advancing treatment options in oncology.
Read more →CLDI▲ +42.6%on this news
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
Calidi Biotherapeutics Inc. announced a new platform designed to deliver genetic medicines to primary and metastatic tumors. This innovative approach utilizes engineered viruses to transport therapeutic payloads, targeting high-need areas, starting with oncology. The company sees significant potential for transforming cancer treatment and is also exploring applications in autoimmune disorders. The announcement highlights the rising global cancer incidence, emphasizing the need for more effective therapies.
Read more →CLDI▲ +109%on this news· ran to +198% by day 1shared move
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Calidi Biotherapeutics announced the immediate exercise of specific warrants, generating approximately $4.6 million in gross proceeds. This move aims to bolster the company's clinical and pre-clinical programs and ensure adequate operational funding. The arrangement allows the issuance of new warrants while the closing of the offering is expected shortly, subject to customary conditions. The capital raised is intended to support the company's pioneering work in targeted therapies and genetic medicine delivery.
Read more →CLDI▲ +39.5%on this news· ran to +216% by day 3shared move
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
Calidi Biotherapeutics Inc. has announced the development of a precision genetic medicine platform that aims to transform cancer treatment. This novel approach utilizes engineered viruses to specifically deliver medicines to tumors, potentially improving treatment outcomes. The company is addressing the urgent need for innovative therapies as cancer incidence rates are projected to rise dramatically in the coming years. Calidi's technology highlights the potential to combat both primary and metastatic cancer effectively.
Read more →CLDICalidi Biotherapeutics Announces Shareholder Letter from CEO
Calidi Biotherapeutics has issued a letter from CEO Eric Poma, detailing transformative changes within the company. Key achievements include leadership restructuring, notable advancements in their R&D pipeline, particularly with the RedTail platform targeting metastatic cancer, and financial improvements. The company remains focused on completing IND-enabling studies and expects to initiate a phase I trial for its SuperNova virotherapy by the end of 2025. Overall, Calidi is optimistic about its future prospects in the biotechnology sector.
Read more →CLDICalidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
Calidi Biotherapeutics presented its lead candidate, CLD-401, at the ASCO Annual Meeting, showcasing advancements in its RedTail platform through a novel CD55 enhancement. This approach aims to improve the systemic delivery of oncolytic therapies for metastatic diseases while enhancing immune responses via an IL-15 superagonist. With ongoing IND-enabling studies and plans for an Investigational New Drug application in 2026, Calidi is actively seeking partnerships to advance its clinical development. The technology aims to address significant unmet medical needs in various cancer indications, but uncertainties remain regarding clinical outcomes and regulatory approvals.
Read more →CLDI▼ -8.5%on this news
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics, a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025, highlighting several key operational developments. The company announced the appointment of Eric Poma, PhD, as CEO and Guy Travis Clifton, MD, as CMO, both bringing extensive biopharmaceutical experience. Additionally, the FDA cleared the IND application for their CLD-201 clinical trial focused on solid tumors, and promising preclinical data regarding their Redtail virotherapy platform was presented at the AACR Annual Meeting. Furthermore, the company's net loss diminished significantly compared to the same period in 2024, indicating improved financial health.
Read more →CLDICalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
Calidi Biotherapeutics has announced the selection of IL15 superagonist as the first payload for its systemic antitumor virotherapy platform, RTNova. This new technology aims to deliver virotherapies directly to tumors, thus potentially improving treatment outcomes for metastatic cancers. Recent preclinical data showcased at the AACR Annual Meeting indicates a notable increase in tumor elimination rates with this approach. The company emphasizes the potential of RTNova to minimize systemic toxicity while boosting immune responses in targeted tumor environments.
Read more →CLDICalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Calidi Biotherapeutics has announced the granting of a non-qualified stock option to its new CEO, Eric Poma, as part of his employment agreement. The stock options, totaling 726,412 shares, will vest over four years, reflecting the company's strategy to attract and retain key leadership. Calidi focuses on developing advanced immuno-oncology treatments utilizing proprietary technology aimed at enhancing cancer therapy efficacy and patient safety. However, the company faces potential challenges related to funding and regulatory approval of its therapeutic candidates.
Read more →CLDICalidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
Calidi Biotherapeutics has announced the appointment of Eric Poma, Ph.D. as the new CEO, succeeding Allan Camaisa, who will remain on the Board. Dr. Poma brings over 30 years of biopharmaceutical experience and will guide the company's ongoing clinical programs, including the upcoming dose escalation trial for CLD-201. The leadership transition aims to enhance shareholder value and drive the company's strategic vision in oncology therapeutics.
Read more →CLDI▲ +6.6%on this newsshared move
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
Calidi Biotherapeutics is hosting a live investor webinar on April 24, 2025, featuring insights from its new Chief Medical Officer, Dr. Guy Travis Clifton. The session will cover the company's innovative stem cell-based therapies for cancer treatment and include a Q&A segment. This event follows the FDA's clearance of Calidi's Investigational New Drug application for its lead therapy, CLD-201.
Read more →CLDICalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
Calidi Biotherapeutics has announced that the FDA has cleared its IND application for CLD-201, an allogeneic stem cell-based immunotherapy aimed at treating solid tumors in adults, including breast cancer, head and neck cancer, and soft tissue sarcoma. Preclinical data supports the potential of CLD-201 to evade the immune system and target cancer cells effectively. The upcoming clinical trials will evaluate the safety and effectiveness of this unique therapy. This clearance is viewed as a major milestone for the company and may provide new hope for patients with challenging cancer types.
Read more →CLDICalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
Calidi Biotherapeutics has appointed Dr. Guy Travis Clifton as Chief Medical Officer, Consultant, and Advisor. With over 17 years of experience in oncology and drug development, Dr. Clifton is expected to significantly contribute to Calidi's goals, particularly in advancing their stem cell-based and enveloped virus platforms. The company recently filed an IND for a clinical trial of their treatment CLD-201 targeting adult patients with solid tumors. Calidi's innovative therapies aim to improve efficacy and patient safety in cancer treatment.
Read more →CLDI▼ -12.9%on this news
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics announced the successful closing of a $3.9 million registered direct offering and concurrent private placement on March 31, 2025. The offering involved the sale of approximately 3.3 million shares and associated warrants to a single institutional investor. The company plans to utilize the net proceeds primarily for working capital and the advancement of its clinical programs focused on cancer treatment. This transaction underscores Calidi's ongoing efforts to enhance its financial position and develop its proprietary immunotherapies.
Read more →CLDI▼ -12.9%on this news
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its fourth quarter and full-year 2024 financial results, noting advancements in its gene therapy platforms and the initiation of several clinical trials for cancer treatments. The company filed an Investigational New Drug (IND) application for its CLD-201 therapy and commenced patient recruitment for the CLD-101 trial at Northwestern University. Financially, Calidi showed a reduced net loss compared to the previous year, though substantial losses persist. The company continues to progress with its innovative approaches in immunotherapy and virotherapy for treating aggressive cancers.
Read more →CLDI▼ -6.5%on this news· ran to -19% by day 1shared move
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics has announced it will raise $3.9 million through a registered direct offering and a concurrent private placement, involving a sale of common stock and pre-funded warrants. The gross proceeds will be used for working capital and to advance the company's clinical and pre-clinical programs. The closing of the offering is expected around March 31, 2025, pending customary conditions. Although this funding may enhance the company's capabilities, risks remain regarding future clinical trials and regulatory approvals.
Read more →CLDICalidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
Calidi Biotherapeutics and City of Hope have provided an update on a Phase 1 clinical trial of CLD-101, a novel virotherapy for treating recurrent high-grade glioma. The trial, which has already enrolled 14 participants, is focusing on evaluating the safety and efficacy of multiple doses administered intracerebrally. Initial results are promising, with all treatment so far being well tolerated. The trial aims to explore higher treatment doses and is also open in notable institutions like Northwestern University and Stanford University.
Read more →CLDI▼ -7.1%on this news
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
Calidi Biotherapeutics announced promising preclinical results for its RTNova platform, which effectively delivers transient gene therapy payloads to tumors. The innovative platform utilizes a modified vaccinia virus that can target distant tumors while inducing a strong immune response. New data indicates that the triple knockout RT virus significantly alters the tumor microenvironment, leading to the complete eradication of certain tumors in preclinical models. The company believes this breakthrough could open doors for developing multiple oncology assets and potential partnerships.
Read more →CLDI▼ -7.5%on this news· ran to -21% by day 3
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
Calidi Biotherapeutics has initiated recruitment for the CLD-101 clinical trial at Northwestern Memorial Hospital, focusing on patients with newly diagnosed high-grade glioma. The trial will explore a multiple dose regime of CLD-101, building on previous promising Phase 1 results. This physician-led study, funded by the NIH/NCI SPORE, aims to enhance treatment efficacy with guidance from leading experts. Successful outcomes could transform glioblastoma treatment.
Read more →CLDIJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
Calidi Biotherapeutics is inviting investors to a live webinar on February 5, 2025, featuring insights from its CFO and CSO on their innovative cancer therapies. The session will cover the company's lead programs and include a live Q&A. This event aims to enhance investor understanding of Calidi's advancements in oncolytic virus therapies.
Read more →CLDICalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
Calidi Biotherapeutics announced a bolstered cash balance of approximately $9.6 million as of December 31, 2024, following successful fundraising efforts, including proceeds from recent public offerings. As a result, the company has terminated its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. This termination is seen as a critical step in enhancing shareholder value and improving financial flexibility. Additionally, Calidi has received FDA clearance for a Phase 1b/2 trial of its candidate CLD-101, which adds to its strategic advancements in virotherapy.
Read more →CLDICalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
Calidi Biotherapeutics has announced that its abstract on the RTNova systemic virotherapy platform has been accepted for presentation at the AACR Annual Meeting in April 2025. This platform aims to target metastatic cancers, which are a leading cause of mortality, by enabling targeted treatment across multiple tumor sites. CEO Allan Camaisa emphasized the transformative potential of this system, indicating significant advancements in cancer therapy. In addition, further data will be revealed at the ASCO Annual Meeting, showcasing Calidi's broader commitment to oncology and its proprietary technologies.
Read more →CLDI▼ -32.2%on this newsshared move
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics Inc. has successfully closed a public offering of 5,000,000 shares of common stock at $0.85 per share, raising approximately $4.25 million. This offering was facilitated by Ladenburg Thalmann & Co. Inc. and was conducted under SEC registration statements that became effective on October 10, 2024. The funds raised are expected to support Calidi's ongoing clinical development of targeted antitumor virotherapies designed to enhance patient safety and efficacy in cancer treatment.
Read more →CLDI▼ -32.2%on this newsshared move
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics announced the pricing of a public offering of 5,000,000 shares of common stock at $0.85 per share, aiming to raise approximately $4.25 million. The offering is in line with a shelf registration statement approved by the SEC. The gross proceeds will support working capital and general corporate purposes. The closing of the offering is anticipated to occur on or about January 10, 2025, pending customary closing conditions.
Read more →CLDI▲ +7.3%on this news
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
Calidi Biotherapeutics presented promising data on its RTNova systemic technology, showcasing its ability to target metastatic lung cancer. The technology is designed to overcome challenges in systemic virotherapy, potentially affecting multiple tumor microenvironments. This advancement may play a significant role in treating previously untreatable metastatic diseases and could lead to collaborations with pharmaceutical partners. The findings were shared at prominent oncological conferences, highlighting the therapeutic potential of their proprietary platform.
Read more →CLDI▲ +9%on this newsshared move
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics has completed a public offering of 4,437,869 shares of common stock, raising approximately $7.5 million at a price of $1.69 per share. This offering, facilitated by Ladenburg Thalmann & Co. Inc., is expected to support Calidi's ongoing development of targeted antitumor virotherapies. The company's innovative technology aims to enhance the immune response against cancer, with applications in multiple oncology indications. The offering's details are filed with the SEC, indicating a focus on transparency and compliance.
Read more →CLDI▼ -40.5%on this newsshared move
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics has announced the pricing of a public offering, intending to raise approximately $7.5 million by selling 4,437,869 shares at a price of $1.69 each. The closing of the offering is anticipated on November 15, 2024, pending customary closing conditions. The funds will be utilized for working capital and various clinical trial phases. Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent for this offering, which is being conducted under an effective shelf registration statement with the SEC.
Read more →CLDI▲ +26.3%on this news· ran to +102% by day 1shared move
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics announced its third quarter 2024 financial results, highlighting key developments such as FDA clearance for its NeuroNova (CLD-101) clinical trial aimed at treating high-grade glioma. The presentation of clinical data for RTNova (CLD-400) at multiple conferences showcased the company's advancements in systemic antitumor virotherapy. Despite raising $2 million through direct offerings, Calidi reported a net loss of $5.1 million, reflecting significant financial challenges.
Read more →CLDICalidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
Calidi Biotherapeutics plans to showcase data supporting its RTNova virotherapy platform at multiple upcoming scientific conferences. Designed as a systemic treatment for metastatic tumors, RTNova targets multiple tumor sites and alters the tumor immune microenvironment, potentially offering new treatment avenues for cancer. Presentations will take place in Rotterdam, San Diego, and Houston from late October to early November 2024, featuring key insights from the company's leading researchers.
Read more →CLDI▼ -26.5%on this newsshared move
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics has announced a $2 million registered direct offering and concurrent private placement with institutional investors. This will involve the sale of 2,050,000 shares at $1.00 each and warrants for additional shares. The proceeds are aimed at supporting working capital, general corporate purposes, and clinical trials. The offerings are expected to close on October 24, 2024, subject to standard conditions, with Ladenburg Thalmann acting as the exclusive placement agent.
Read more →CLDINYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) SAN DIEGO-(GLOBE NEWSWIRE)- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi"), a clinical
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) has announced that the NYSE Regulation staff has started delisting proceedings for its warrants (ticker: CLDI WS) due to a low trading price. As a result, trading for these warrants will be suspended, although trading for the company's common stock will continue. The company has the option to appeal this decision to the Listings Qualifications Panel and is expected to undergo a review process before the final delisting occurs.
Read more →CLDI▼ -5.8%on this news
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Calidi Biotherapeutics has received FDA clearance for the IND application of CLD-101, a novel immunotherapy targeting high-grade glioma. The Phase 1b/2 clinical trial is set to begin in late 2024, investigating the safety and feasibility of CLD-101 in combination with existing therapies. This development follows promising results from earlier studies, highlighting the potential of CLD-101 in treating one of the most challenging cancers. The enthusiasm from both Calidi executives and academic leaders underscores optimism for advancing this therapeutic option.
Read more →CLDI▼ -5.7%on this news
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics reported its second quarter 2024 results, highlighting a $2 million investment into its new subsidiary Nova Cell to advance stem cell programs. Key appointments to the board were announced, including notable experts in oncology, which is expected to strengthen the company's direction. The company also secured a U.S. patent for its SuperNova technology geared towards cancer treatment. However, Calidi reported a net loss of $5.8 million in Q2, despite a decrease in losses compared to the same period last year.
Read more →CLDICalidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
Calidi Biotherapeutics has announced the launch of its subsidiary, Nova Cell, and a $3 million investment from Dr. Ronald Rigor to enhance its stem cell programs. The investment includes $2 million to support Nova Cell and an additional $1 million to advance Calidi's oncology pipeline. Dr. Rigor, a recognized expert in stem cell therapy, will join Calidi's Scientific and Medical Advisory Board, expanding the company's regenerative medicine efforts in the Philippines. This new focus aims to develop a range of therapies leveraging Adult Adipose Allogeneic stem cells from healthy donors to treat various conditions beyond oncology.
Read more →CLDI▼ -8.4%on this news
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
Calidi Biotherapeutics has announced the issuance of a U.S. patent for its SuperNova technology platform, which is aimed at advancing its CLD-201 program into clinical trials. The patent enhances the company's intellectual property portfolio and focuses on immunotherapy methods combining a smallpox vaccine with stem cells. CEO Allan Camaisa emphasized the significance of this development in addressing the needs of patients with advanced solid tumors. The company anticipates initiating first-in-human clinical trials as it continues to evaluate the safety and efficacy of its therapy.
Read more →CLDI▲ +7.4%on this newsshared move
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Calidi Biotherapeutics announced the appointment of Dr. Mark Gilbert to its Medical Advisory Board, enhancing its expertise with a seasoned neuro-oncologist. Dr. Gilbert, formerly Chief of the Neuro-Oncology Branch at the NIH, has a strong background in the development of clinical trials targeting brain tumors. His addition is expected to guide innovative research and collaborative studies aimed at improving cancer treatments. This appointment reflects Calidi's commitment to advancing its novel stem cell-based therapies.
Read more →CLDICALIDI TO EFFECT REVERSE STOCK SPLIT CALIDI common stock expected to begin trading on a 1-for-10 split adjusted basis on
Calidi Biotherapeutics Inc. has announced a 1-for-10 reverse stock split, effective July 15, 2024. This decision was approved by the Board of Directors following a Special Meeting of Stockholders. The company's common stock will begin trading on a split-adjusted basis under the symbol CLDI. Despite the stock split, challenges remain due to uncertainties surrounding clinical trials and potential FDA approvals for their therapies.
Read more →CLDICalidi to Effect Reverse Stock Split
Calidi Biotherapeutics has announced a reverse stock split of its common stock at a 1-for-10 ratio, effective July 15, 2024. This decision was approved by the Board of Directors and aims to consolidate shares to potentially increase stock value. The split will not affect the number of authorized shares or the par value per share.
Read more →CLDICalidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
Calidi Biotherapeutics has appointed Dr. George E. Peoples to its Board of Directors, effective July 1, 2024. Dr. Peoples is a renowned expert in cancer immunotherapy with over 20 years of experience in cancer vaccine development. His expertise is expected to significantly contribute to Calidi's advancement of its cancer immunotherapy portfolio into later-stage clinical trials.
Read more →CLDI▲ +31.7%on this news
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
Calidi Biotherapeutics is hosting a live investor webinar on June 13, 2024, featuring insights from key executives about their innovative oncolytic virotherapy technologies. The company is focused on developing targeted immunotherapies to treat cancer, leveraging engineered viruses to enhance treatment efficacy. Attendees will have the opportunity to engage in a live Q&A session.
Read more →CLDI▲ +6.2%on this news· ran to +40% by day 1shared move
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy platform aimed at treating lung cancer and metastatic solid tumors. This collaboration will utilize SIGA's TPOXX antiviral to enhance the safety and efficacy of RTNova. The innovative approach of RTNova is designed to target multiple tumor sites while evading human immunity, potentially transforming cancer treatment.
Read more →CLDI▲ +15.8%on this news
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
Calidi Biotherapeutics presented updates on its CLD-101 Phase 1 trial and preclinical data for RTNova and CLD-201 at the 2024 ASCO Annual Meeting. The Phase 1 trial showed positive safety and feasibility results, with ongoing patient enrollment. The RTNova platform demonstrated effective tumor targeting in preclinical models, while Calidi plans to initiate a Phase 1 trial for CLD-201 soon.
Read more →CLDI▼ -36.7%on this newsshared move
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Calidi Biotherapeutics announced the exercise of Series B and C warrants for approximately $2.1 million in gross proceeds. The financing will help advance its clinical programs focused on innovative cancer therapies. As part of the agreement, new warrants will also be issued. The offering is expected to close shortly, contingent upon customary closing conditions. The company plans to use the net proceeds for ongoing operational expenses and further development.
Read more →CLDICalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi's CLD-101 program, to be presented at 2024 ASCO Annual Me
Calidi Biotherapeutics reported its financial results for the first quarter of 2024, highlighting a net loss of $7.2 million. The company will present updates on its ongoing Phase 1 trial of the CLD-101 program at the upcoming ASCO Annual Meeting. Additionally, Calidi showcased new data supporting its immunotherapy platforms during the AACR Annual Meeting. While Calidi's novel treatment approaches show promise, the company also faces challenges, including increased expenses and the necessity to raise further capital for its operations.
Read more →CLDICalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics reported its first quarter 2024 results, highlighting upcoming presentations at the ASCO Annual Meeting and new data on its immunotherapy programs. The company successfully raised $6.1 million to support its operations. However, it also reported a net loss of $7.2 million, emphasizing the need for further capital to advance its clinical trials.
Read more →CLDICalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Calidi Biotherapeutics has announced the acceptance of three abstracts for presentation at the 2024 ASCO Annual Meeting. The presentations will include updates on the CLD-101 program for treating recurrent high-grade gliomas and preclinical data on the RTNova delivery platform. The company aims to advance its clinical trials, including the upcoming CLD-201 trial, pending capital acquisition.
Read more →CLDICalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics has successfully closed a public offering, raising approximately $6.1 million through the sale of 15,197,500 shares and warrants. The funds will be allocated towards working capital, clinical trials, and debt repayment. The company focuses on developing targeted immunotherapies using allogeneic stem cells to combat various cancers.
Read more →CLDICalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering San Diego, Calif.
Calidi Biotherapeutics, Inc. announced the successful closing of its public offering, generating gross proceeds of approximately $6.1 million. The offering, which included common stock and various warrants, will support the company’s working capital, pre-clinical and clinical trials, as well as repayment of certain debt. The funds raised underscore confidence from investors in Calidi’s innovative immunotherapy technologies. However, the company also faces potential risks regarding the financing of clinical trials and the approval of its therapeutics by the FDA.
Read more →CLDI▼ -65.5%on this newsshared move
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. has announced the pricing of a public offering, aiming to raise approximately $6.1 million through the sale of 15,197,500 shares and various warrants. The offering is set to close around April 18, 2024, pending customary conditions. Proceeds will support working capital and clinical trials, although the company faces potential risks regarding capital sufficiency and FDA approvals.
Read more →CLDI▲ +62.4%on this news· ran to +83% by day 3
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
Calidi Biotherapeutics presented new data at the AACR Annual Meeting 2024, highlighting the mechanisms of action for its stem cell-based immunotherapies, CLD-101 and CLD-201. These therapies aim to enhance antitumor activity by cloaking oncolytic viruses from the immune system. The presentation emphasized the potential of these therapies to improve treatment outcomes for solid tumors. Calidi is also advancing clinical trials, with updates expected in the near future.
Read more →CLDICalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results - City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerat
Calidi Biotherapeutics reported its fourth quarter and full-year 2023 results, highlighting significant advancements in its treatment programs. Notably, City of Hope received $5.3 million from CIRM to aid in developing an ovarian cancer treatment using Calidi's NeuroNova asset, CLD-101. The company also announced the launch of a new platform, RTNova, aimed at targeting diverse solid tumors, alongside the issuance of a patent for its SuperNova technology. Despite these developments, Calidi reported substantial financial losses and emphasized the necessity of raising additional capital for ongoing trials.
Read more →CLDICalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
Calidi Biotherapeutics and City of Hope announced a $5.3 million grant from CIRM to advance CLD-101, a treatment for metastatic ovarian cancer. The funding will support preclinical studies and clinical trial design. CLD-101 utilizes neural stem cells to deliver an oncolytic adenovirus directly to tumor sites, potentially improving outcomes for patients resistant to chemotherapy.
Read more →CLDICalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
Calidi Biotherapeutics announced its upcoming presentation on a novel systemic enveloped oncolytic virotherapy platform, ImmunoNova, at the Biocom Global Life Science Partnering & Investor Conference. This innovative approach aims to target various advanced tumors and has shown promising preclinical results. The platform leverages engineered vaccinia viruses to enhance immune responses against metastatic diseases.
Read more →CLDI▼ -6.3%on this news· ran to -26% by day 3
Scientific Advisory Board Member Interview – W.K. Alfred Yung, M.D.
The article features an interview with W.K. Alfred Yung, M.D., a member of the Scientific Advisory Board. It emphasizes his insights and contributions to the field of oncology. The interview is part of a series showcasing key figures in biotherapeutics. The discussion is expected to provide valuable perspectives on cancer therapies.
Read more →CLDI▼ -6.3%on this news· ran to -26% by day 3
Scientific Advisory Board Member Interview – Santosh Kesari, M.D./Ph.D.
The article features an interview with Santosh Kesari, M.D./Ph.D., a member of the Scientific Advisory Board. It is part of a series of interviews with advisory board members, showcasing their insights and contributions. The article does not provide specific details about the interview content or topics discussed.
Read more →CLDI▼ -6.3%on this news· ran to -26% by day 3
Scientific Advisory Board Member Interview – Bernard Fox, Ph.D.
The article features an interview with Bernard Fox, Ph.D., a member of the Scientific Advisory Board. It is part of a series of interviews highlighting various board members. The piece does not provide specific insights or details about Dr. Fox's contributions or perspectives.
Read more →CLDI▼ -6.3%on this news· ran to -26% by day 3
Scientific Advisory Board Member Interview – Ashok Srivastava, M.D./Ph.D.
The article features an interview with Dr. Ashok Srivastava, a member of the Scientific Advisory Board at Calidi Biotherapeutics. It emphasizes his contributions and insights into the field of biotherapeutics. This interview is part of a series highlighting the expertise of advisory board members.
Read more →CLDI▲ +6.8%on this news
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
Calidi Biotherapeutics has appointed three prominent experts to its Scientific and Medical Advisory Board, enhancing its capabilities in cancer research. The new members include Dr. Antonio Chiocca, Dr. David T. Curiel, and Dr. Burt L. Nabors, who are recognized leaders in oncology. Their expertise is expected to support the development of Calidi's novel immunotherapies targeting high-grade gliomas and solid tumors.
Read more →CLDICalidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
Calidi Biotherapeutics announced three presentations at the 8th Oncolytic Virotherapy Summit, focusing on their NeuroNova and SuperNova platforms. The presentations will cover the clinical trial design and safety of a Phase 1 study for recurrent high-grade glioma, updates on targeted immunotherapies, and plans for future clinical trials. The company aims to advance its innovative virotherapy approaches to combat various cancers.
Read more →CLDICalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
Calidi Biotherapeutics has appointed David LaPré to its Board of Directors, effective January 1, 2024. LaPré brings extensive experience in the pharmaceutical industry, particularly in technical operations and supply chain management. The company also announced the resignations of two directors, Alfonso Zulueta and Tom Vecchiolla. This leadership change aims to strengthen Calidi's focus on advancing its cancer immunotherapy portfolio.
Read more →CLDICalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
Calidi Biotherapeutics has announced the issuance of a new U.S. patent for its SuperNova technology, enhancing its intellectual property and paving the way for the CLD-201 program to enter clinical trials. The patent covers innovative methods for oncolytic viral therapy using stem cells. The company also provided updates on upcoming clinical milestones, including the initiation of trials for both NeuroNova and SuperNova platforms in 2024.
Read more →CLDICalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
Calidi Biotherapeutics reported its Q3 2023 financial results, highlighting the dosing of the first patient in a Phase 1 trial for CLD-101 in recurrent high-grade glioma patients. The company also presented promising preclinical data for its CLD-201 platform at SITC 2023. Despite a net loss of $2.0 million, Calidi is optimistic about its future clinical developments and leadership appointments.
Read more →CLDICalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results Announced first patient dosed by collaborator City of Hope in a Phase 1 clinical trial evaluating CLD-101 in recurrent high-grade glioma p
Calidi Biotherapeutics has announced its financial results for Q3 2023, highlighting the dosing of the first patient in a Phase 1 trial for recurrent high-grade glioma in collaboration with the City of Hope. The company also presented encouraging preclinical data for its CLD-201 program at the SITC annual meeting. Leadership changes were made, including the appointment of a new CFO. Despite a significant net loss, the firm remains optimistic about its clinical advancements and upcoming trials planned for 2024.
Read more →CLDI▲ +18.9%on this news
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
Calidi Biotherapeutics presented promising preclinical data on CLD-201 at the SITC 2023 meeting. The data indicates that CLD-201 effectively inhibits tumor growth and induces strong anti-tumor immunity in various models. The company is preparing to launch a Phase 1 clinical trial in 2024, highlighting the product's readiness and potential advantages over existing therapies.
Read more →CLDICalidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
Calidi Biotherapeutics has announced significant leadership changes, promoting Antonio Santidrian to Chief Scientific Officer and Amish Patel to Senior Vice President of Technical Operations. Additionally, Alan Stewart has been appointed to the Board of Directors, replacing Dr. Heehyoung Lee. These changes aim to strengthen the company's focus on developing targeted immunotherapies.
Read more →CLDICalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer San Diego, Calif.
Calidi Biotherapeutics has appointed Andrew Jackson as Chief Financial Officer, who brings over 25 years of experience in corporate finance. Jackson's background includes significant roles in publicly traded companies and successful financing efforts exceeding $300 million. The CEO expressed confidence that Jackson's expertise will aid in advancing the company’s novel immunotherapy platforms aimed at treating cancer. This leadership change coincides with Calidi's mission to employ innovative stem cell technologies in oncology.
Read more →CLDICalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
Calidi Biotherapeutics has appointed Andrew Jackson as its new Chief Financial Officer. With over 25 years of experience in corporate finance, Jackson is expected to leverage his expertise to support Calidi's growth and advance its immunotherapy platforms. His previous roles include CFO positions at Eterna Therapeutics and Ra Medical Systems.
Read more →CLDICalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
Calidi Biotherapeutics will present new preclinical data on its SuperNova technology at the SITC 2023 annual meeting. The poster will detail the company's novel stem cell-based platform designed to enhance oncolytic virotherapies for cancer treatment. The presentation is scheduled for November 3, 2023, in San Diego, CA.
Read more →CLDIAnalyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
Calidi Biotherapeutics has garnered positive attention from analysts following its debut as a publicly traded company. The firm aims to revolutionize cancer treatment by developing targeted immunotherapies that empower the immune system. This innovative approach positions Calidi as a promising player in the competitive cancer treatment market.
Read more →CLDICalidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
Calidi Biotherapeutics is emerging as a notable entity in the cancer treatment sector. The company will showcase new preclinical data on its SuperNova platform technology at the upcoming SITC 2023 conference. Analysts express a positive outlook on Calidi's prospects in the oncology market, highlighting its innovative approaches.
Read more →CLDICALIDI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ( In thousands, except for par value data )
CALIDI Biotherapeutics, Inc. released its condensed consolidated balance sheets for June 30, 2023, showing a notable increase in total assets to $10,179,000, compared to $2,597,000 on December 31, 2022. However, the company reported a net loss of $18,963,000 for the first half of 2023, indicating a deterioration in financial performance relative to the previous year. Liabilities rose significantly, amounting to $64,287,000, raising concerns about the company's financial health and sustainability moving forward.
Read more →CLDICalidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
Calidi Biotherapeutics has completed its business combination with First Light Acquisition Group, resulting in around $28 million in gross proceeds. The company, now listed on the NYSE under ticker CLDI, is dedicated to advancing its targeted immunotherapy platforms for cancer treatment, including CLD-101 and CLD-201. These platforms utilize allogeneic stem cells and are currently in various stages of clinical trials aimed at treating high-grade gliomas and advanced solid tumors. With further funding arrangements in place, Calidi is poised to extend its research through 2025.
Read more →CLDIFirst Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments Business combination transaction with Calidi Biotherapeutics an
First Light Acquisition Group has announced that its business combination with Calidi Biotherapeutics is set to finalize on September 12, 2023. This transaction will provide Calidi with $28 million in gross proceeds, enabling it to advance its business plans. Additionally, a forward purchase agreement has been secured for up to $10 million with a consortium of investors. Following completion, shares will commence trading on the NYSE under the ticker symbols CLDI and CLDI WS on September 13, 2023.
Read more →CLDICalidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
Calidi Biotherapeutics, a clinical-stage biotechnology company, will present at the Baird Global Healthcare Conference on September 13, 2023. CEO Allan Camaisa and Chief Business Officer Stephen Thesing will participate in a fireside chat. The company focuses on targeted immunotherapies and is developing a novel stem cell-based therapy for cancer treatment.
Read more →CLDIFIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to
First Light Acquisition Group, Inc. has announced the further adjournment of its Special Meeting of Stockholders to August 28, 2023. The meeting, which previously convened and adjourned on August 22, will consider a business combination with Calidi Biotherapeutics. This postponement does not affect stockholders who have already voted and may lead to delays in the proposed merger's execution.
Read more →CLDIFIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to
First Light Acquisition Group, Inc. announced the adjournment of its Special Meeting of Stockholders to August 24, 2023. The meeting aims to discuss and vote on the business combination with Calidi Biotherapeutics, Inc. Stockholders who previously voted do not need to take further action. The adjournment may raise concerns among investors regarding the completion of the proposed transaction.
Read more →CLDIThe following is a presentation for use by Calidi Biotherapeutics, Inc. and First Light Acquisition Group (FLAG) at an analyst day on
Calidi Biotherapeutics, Inc. is presenting at an analyst day concerning a proposed business combination with First Light Acquisition Group (FLAG). This presentation emphasizes their innovative stem cell therapy designed to combat cancer. However, it also highlights various risks and uncertainties linked to the business combination, including potential shareholder approvals and ongoing legal proceedings. As the companies navigate this process, both operational plans and market conditions may significantly influence the outcome.
Read more →CLDICalidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
Calidi Biotherapeutics and City of Hope have announced the dosing of the first patient in a Phase 1 clinical trial evaluating CLD-101, an innovative treatment using neural stem cells to deliver an oncolytic virus for recurrent high-grade glioma. The trial aims to assess the safety and preliminary efficacy of this therapy, which has shown potential in preclinical studies. This milestone marks a significant step in developing new treatment options for patients with difficult-to-treat brain cancers.
Read more →CLDICalidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Calidi Biotherapeutics has announced a commitment of $25 million in Series B funding, primarily led by Jackson Investment Group, to further develop its innovative stem cell-based platforms for delivering oncolytic viruses in cancer treatment. This financing is crucial for advancing several clinical products in the company's pipeline. However, the full commitment is contingent upon the successful merger with First Light Acquisition Group, which introduces uncertainties regarding regulatory approvals and other negotiating conditions. Overall, the funding reflects significant investor confidence in Calidi's approach to addressing cancer treatment challenges.
Read more →CLDIRevolutionizing Cancer Therapies with a Durable and Systemic Antitumor Immune Response Utilizing Allogeneic Stem Cell-Based Platforms to Deliver and Potentiate Oncolytic Therapies www.calidibio.com February 2023 Forward-
Calidi Biotherapeutics, Inc. is in discussions for a proposed business combination with First Light Acquisition Group, Inc. The collaboration aims to advance Calidi's innovative use of allogeneic stem cell-based platforms for delivering oncolytic therapies to combat cancer. However, the deal is subject to multiple approvals and carries inherent risks, such as uncertainties related to shareholder support and adherence to stock exchange requirements. The overall success of the integration and its impact on the market remains to be fully assessed.
Read more →CLDICalidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
Calidi Biotherapeutics and First Light Acquisition Group have entered a merger agreement aimed at creating a publicly listed clinical-stage biotechnology company. This merger will combine resources to support Calidi's development of oncolytic virotherapy platforms utilizing stem cell technology. The transaction is anticipated to complete by the second quarter of 2023, providing significant cash resources expected to facilitate the advancement of Calidi's clinical programs through 2025. The combined entity will trade on the NYSE American under the ticker CLDI.
Read more →CLDIFIRST LIGHT ACQUISITION GROUP, INC. ANNOUNCES APPROVAL OF EXTENSION AMENDMENT TO CERTIFICATE OF INCORPORATION New York, New York
FIRST LIGHT ACQUISITION GROUP, INC. ANNOUNCES APPROVAL OF EXTENSION AMENDMENT TO CERTIFICATE OF INCORPORATION New York, New York December 15, 2022 First Light Acquisition Group, Inc. (NYSE: FLAG) ( FLAG ) today announced that its Board of Directors approved an extension of the
Read more →CLDIFirst Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC
First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC WIRE) First Light Acquisition Group, Inc. (NYSE: FLAG) ( FLAG ), a special purpose acquisition company, announced today that it will transfer its listing to the NYSE American LLC ( NYSE American ), where
Read more →CLDIWeil Draft 9/8/2022 FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to
FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to September 13, 2022 at 10:00 am ET New York, New York September 9, 2022 First Light Acquisition Group, Inc. (NYSE: FLAG) ( FLAG ) today announced that it convened and then adjourned, without conducti
Read more →CLDICalidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through
Read more →CLDIFirst Light Acquisition Group, Inc. Announces the Separate Trading of its shares of Class A Common Stock and Warrants, Commencing
Acquisition Group, Inc. Announces the Separate Trading of its shares of Class A Common Stock and Warrants, Commencing November 1, 2021 NEW YORK, NY, October 28, 2021 First Light Acquisition Group, Inc. (the Company ) announced that commencing November 1, 2021, holders of the un
Read more →CLDIFIRST LIGHT ACQUISITION GROUP, INC. INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
FIRST LIGHT ACQUISITION GROUP, INC. INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of September 14, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockhold
Read more →CLDIFirst Light Acquisition Group, Inc. Announces Pricing of $200 Million Initial Public Offering
First Light Acquisition Group, Inc. Announces Pricing of $200 Million Initial Public Offering NEW YORK, NY September 9, 2021 First Light Acquisition Group, Inc. (the Company ), a blank check company formed for the purpose of entering into a merger, capital stock exchange, asse
Read more →Competitive Position
How CLDI ranks across every disease it competes inCompetitive Position is a premium feature
See how CLDI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial